AR085105A1 - Dosificacion para tratamiento con anticuerpos anti-dominio 7 de tipo de factor de crecimiento epidermico (anti-egfl7) - Google Patents
Dosificacion para tratamiento con anticuerpos anti-dominio 7 de tipo de factor de crecimiento epidermico (anti-egfl7)Info
- Publication number
- AR085105A1 AR085105A1 ARP120100326A ARP120100326A AR085105A1 AR 085105 A1 AR085105 A1 AR 085105A1 AR P120100326 A ARP120100326 A AR P120100326A AR P120100326 A ARP120100326 A AR P120100326A AR 085105 A1 AR085105 A1 AR 085105A1
- Authority
- AR
- Argentina
- Prior art keywords
- egfl7
- dosage
- growth factor
- epidermal growth
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Dosificación de anticuerpos anti-dominio 7 de tipo de factor de crecimiento epidérmico (anti-EGFL7) para tratamiento del cáncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161438944P | 2011-02-02 | 2011-02-02 | |
US201161492743P | 2011-06-02 | 2011-06-02 | |
US201261587382P | 2012-01-17 | 2012-01-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR085105A1 true AR085105A1 (es) | 2013-09-11 |
Family
ID=46603300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120100326A AR085105A1 (es) | 2011-02-02 | 2012-02-01 | Dosificacion para tratamiento con anticuerpos anti-dominio 7 de tipo de factor de crecimiento epidermico (anti-egfl7) |
Country Status (11)
Country | Link |
---|---|
US (1) | US20130004498A1 (es) |
EP (1) | EP2670437A2 (es) |
JP (1) | JP2014510044A (es) |
KR (1) | KR20140012080A (es) |
CN (1) | CN103476430A (es) |
AR (1) | AR085105A1 (es) |
BR (1) | BR112013019080A2 (es) |
CA (1) | CA2825969A1 (es) |
MX (1) | MX2013008922A (es) |
RU (1) | RU2013140471A (es) |
WO (1) | WO2012106473A2 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GEP201706612B (en) | 2011-09-02 | 2017-02-10 | Novamedica Llc | Methods for the treatment of breast cancer |
WO2014186193A1 (en) * | 2013-05-17 | 2014-11-20 | Abwiz Bio, Inc. | T regulatory cells and uses thereof |
CA3061505A1 (en) | 2017-04-24 | 2018-11-01 | Ohio State Innovation Foundation | Recombinant egfl7, egfl7 antibodies, and uses thereof |
US20190167790A1 (en) * | 2017-12-05 | 2019-06-06 | Abbvie Biotherapeutics Inc. | Abt-165 in combination with folinic acid, 5-fluorouracil, and irinotecan for the treatment of cancers |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR059851A1 (es) * | 2006-03-16 | 2008-04-30 | Genentech Inc | Anticuerpos de la egfl7 y metodos de uso |
AU2010245739B2 (en) * | 2009-05-08 | 2013-07-11 | Genentech, Inc. | Humanized anti-EGFL7 antibodies and methods using same |
-
2012
- 2012-02-01 US US13/364,135 patent/US20130004498A1/en not_active Abandoned
- 2012-02-01 KR KR1020137023038A patent/KR20140012080A/ko not_active Application Discontinuation
- 2012-02-01 EP EP12742541.1A patent/EP2670437A2/en not_active Withdrawn
- 2012-02-01 RU RU2013140471/15A patent/RU2013140471A/ru unknown
- 2012-02-01 CA CA2825969A patent/CA2825969A1/en not_active Abandoned
- 2012-02-01 WO PCT/US2012/023547 patent/WO2012106473A2/en active Application Filing
- 2012-02-01 AR ARP120100326A patent/AR085105A1/es not_active Application Discontinuation
- 2012-02-01 BR BR112013019080A patent/BR112013019080A2/pt not_active Application Discontinuation
- 2012-02-01 CN CN2012800151104A patent/CN103476430A/zh active Pending
- 2012-02-01 JP JP2013552611A patent/JP2014510044A/ja active Pending
- 2012-02-01 MX MX2013008922A patent/MX2013008922A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN103476430A (zh) | 2013-12-25 |
CA2825969A1 (en) | 2012-08-09 |
WO2012106473A2 (en) | 2012-08-09 |
WO2012106473A3 (en) | 2012-11-01 |
JP2014510044A (ja) | 2014-04-24 |
MX2013008922A (es) | 2013-10-01 |
RU2013140471A (ru) | 2015-03-10 |
BR112013019080A2 (pt) | 2019-06-11 |
EP2670437A2 (en) | 2013-12-11 |
WO2012106473A8 (en) | 2013-06-06 |
US20130004498A1 (en) | 2013-01-03 |
KR20140012080A (ko) | 2014-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201400178A1 (ru) | Лечение рака молочной железы | |
HK1221646A1 (zh) | 高劑量普利多匹定用於治療亨廷頓舞蹈症的用途 | |
ES2765949T8 (es) | Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer | |
EA201491447A1 (ru) | Ендиины, их конъюгаты и способы их получения и применения | |
CL2015002932A1 (es) | Inhibidores de proteína quinasa | |
GT201500051A (es) | Inhibidores de glucosilceramida sintasa | |
UY34472A (es) | Derivados modificados de 4-fenil-piridina | |
CL2012003385A1 (es) | Tratamiento para la incontinencia. | |
UY35399A (es) | Conjugados de fármacos con anticuerpos | |
UY33627A (es) | Compuestos para tratar enfermedades neurodegenerativas | |
UY34885A (es) | Proteínas de unión anti-mesotelina | |
UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
MX361218B (es) | Análogos de spliceostatina. | |
UY34550A (es) | Bencilpirazoles sustituidos | |
EA201171367A1 (ru) | Винилиндазолильные соединения | |
UY34503A (es) | ?sal de bromhidrato de pridopidina? | |
UY34201A (es) | Compuestos de azaindol y métodos para el tratamiento de vih. | |
BR112013024211A2 (pt) | tratamento de tumores sólidos | |
UY34132A (es) | Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab. | |
UY34467A (es) | Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
UY34661A (es) | Inhibidores de benzodioxano de la producción de leucotrieno para terapia de combinación | |
UY34812A (es) | Método para el tratamiento del cáncer de pulmón de células no pequeñas | |
UY34582A (es) | Anticuerpos anti-cxcr3 | |
GEP201706612B (en) | Methods for the treatment of breast cancer | |
EA201590359A1 (ru) | Лечение ревматоидного артрита |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |